Skip to content
Gold Mining News – Lifestyle
Home
Sample Page
Author:
Medicus Pharma Ltd
Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome
June 15, 2026
Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program
June 11, 2026
Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission
June 8, 2026
Medicus Pharma Advances SkinJect® into Registrational Development for Gorlin Syndrome
June 3, 2026
Medicus Pharma Announces $22 Million Non-Dilutive Financing
May 28, 2026
Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 14, 2026
Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response
May 6, 2026
Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill
April 27, 2026
Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome
April 17, 2026
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression
April 15, 2026
1
2
Next Page
→